New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...

Voyager Therapeutics said it will assess alternate payloads related to its gene therapeutic program related to a form of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

Voyager Therapeutics (VYGR) has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 amyotrophic ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to assess alternate payloads related to its gene ...

A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...

ZEPHYRHILLS — Former Zephyrhills High football coach Tom Fisher, who spent the better part of two decades carving highly ...

The crowd surged into the freezing Atlantic Ocean in the latest in a series of winter plunges at the Jersey Shore.

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a Michigan Medicine-led study suggests.